| Old Articles: <Older 6541-6550 Newer> |
|---|
 |
The Motley Fool
August 9, 2010
Brian Orelli |
Dendreon's in Trouble Provided you call a slap on the wrist from the FDA "trouble."   |
The Motley Fool
August 9, 2010
Luke Timmerman |
Kaleetan Seeks to Stand on Dendreon's Shoulders Kaleetan Pharmaceuticals tries to improve upon Dendreon's breakthrough cancer drug. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
August 9, 2010
Luke Timmerman |
Affymax Lives to Fight Another Day Affymax takes on Amgen with its anemia drug. |
Insurance & Technology
August 6, 2010
Nathan Golia |
WellPoint Providing Financing for Health IT WellPoint hopes that favorable interest rates on loans and other financial incentives will ease adoption of technology among rural hospitals and other providers. |
The Motley Fool
August 6, 2010
Seth Jayson |
Show Me the Money, AstraZeneca With questionable cash sources composing 13% of the cash flow from operations for AstraZeneca, I think it's time to do a little more digging. |
The Motley Fool
August 6, 2010
Bryan Hinmon |
Moat Report Card: Medtronic This medical supplier's definitely got a heartbeat. |
InternetNews
August 5, 2010 |
Another Laptop Theft Exposes 21K Patients' Data Philadelphia's Thomas Jefferson University Hospital is in the process of notifying more than 21,000 patients that a stolen laptop has exposed some of their most sensitive personal information. |
The Motley Fool
August 5, 2010
Seth Jayson |
Show Me the Money, Alcon With questionable cash sources comprising 4% of the cash flow from operations for Alcon, I am pretty confident things are OK. |
BusinessWeek
August 5, 2010
Bennett & Randall |
AIDS Drugs Flow to the Third World Drugmakers, once blasted for their practices, are slashing prices and licensing AIDS drugs for free to nonprofits or local manufacturers in developing countries. |
| <Older 6541-6550 Newer> Return to current articles. |
